Guide · Drug discovery

Reliable AI for Drug Discovery: Controlling Hallucination on the Decisions That Cost Years

In drug discovery, an AI that sounds confident and is quietly wrong is expensive in a way few tools are. A fabricated citation, a mislabelled structure, or an overstated selectivity claim can send a program down a path that costs years and millions. The practical answer is not a smarter model. It is a system that checks its own work against the evidence, says plainly what it cannot support, and keeps a record your scientists, your committee, and a regulator can all audit.

Where a hallucination actually costs you

The damage is rarely a single wrong sentence. It is a wrong sentence that a team acts on. A target advanced on a rationale that does not hold. A series pushed forward on a property that was overstated. A candidate triaged in or out on a selectivity claim nobody checked. A literature citation that looks real and supports a point the source never made, which is one of the best-documented ways AI fails in science.

In each case the output arrived in the same confident, well-formatted voice a correct answer would have. That is the problem with judging an AI result by how it reads: the tone you instinctively trust is exactly the tone the failure produces. The cost shows up later, as wasted synthesis, a dead program, a delayed filing, or a claim that does not survive review.

What reliable AI looks like in practice

Reliability here is not the absence of error. It is error that cannot hide. In a drug- discovery setting that means four practical things:

• It checks claims against the evidence, not against its own confidence.
• It labels how it knows each thing (published fact, computed result, or estimate), so your team sees exactly where the science is solid and where it is guessing.
• It refuses when the data is not there, instead of inventing a number that looks plausible.
• It keeps the full reasoning trail, so a decision can be defended to a committee or a regulator rather than taken on faith.

What we saw it do on a real target

We ran ThinkerWave on a public kinase-selectivity design problem (CDK2). We are describing how it behaved, not making a scientific claim, and this is the behaviour that matters for a team deciding whether to trust it:

It worked out the right standards on its own. It started with a generic checklist and ended up judging its own work against the standards a specialist would actually apply: requiring structural evidence before accepting a selectivity claim, insisting synthetic accessibility be quantified rather than eyeballed, and tagging every quantitative claim as published, computed, or estimated. Nobody wrote those standards into the prompt. It discovered that they mattered.

It caught a factual error in its own instructions. The problem statement referenced the wrong protein-structure code, one that belongs to a different kinase. Instead of quietly building on the mistake, it flagged it. A tool that trusts its inputs blindly cannot do that, and in R&D the mistake in the brief is often the expensive one.

It held two conflicting directions open, then merged them. When tightening one property pulled against adding a new line of structural analysis, it explored both rather than committing early to one and hoping. The result carried what each direction found, with the trade-off made explicit.

The practical takeaway: on a real design problem it behaved like a careful team member who shows the receipts, says what it is not sure of, and catches mistakes, including its own and yours.

Why “runs on your machine” matters more in pharma

Your targets, your series, your molecules, and your pipeline are the company. Sending them to a vendor’s cloud to be analysed is a real intellectual-property and confidentiality risk, and often a non-starter with legal. ThinkerWave runs on your own machine and calls the model provider you already use, under your own credentials. Your data goes to that provider and never to us. There is no ThinkerWave cloud collecting your work. For a discovery team, that is frequently the difference between being allowed to use a tool at all and not.

How a team actually uses it

Point it at the decision you cannot afford to get wrong: which target to back, which series to advance, whether a selectivity story holds up. Describe the problem the way you would to a colleague and attach what you have. It works the problem from several independent angles, surfaces the risks and the weak evidence a single pass would walk past, and hands back a recommendation with its reasoning and its confidence attached.

Your scientists stay accountable. The system does the exhausting cross-checking and shows the trail; the expert makes the call with more in front of them, not less. It is built for the handful of program-shaping decisions a quarter that are worth being careful about, not the hundred routine lookups a day.

Frequently asked questions